The popularity of weight loss drugs has reached a fever pitch in the United States. This trend has made its way into the workplace, with employees increasingly asking their employers about coverage for popular drugs used for weight loss, such as Wegovy. Other drugs intended to treat Type 2 diabetes, such as Ozempic or Mounjaro, are also in high demand for off-label weight-loss use. As a result, employers are presented with the decision of whether to cover these expensive drugs or face potential negative attraction and retention repercussions in the coming years, if not already.

Ozempic is an injectable prescription medication to help adults with Type 2 diabetes manage their blood sugar. Although it’s not approved as a weight-loss drug, people without Type 2 diabetes have begun using Ozempic off-label for this purpose.